

Large Populations And High Economic Growth Rates Offer The Best Opportunities For Neurology Drug Manufacturers


LONDON, GREATER LONDON, UK, October 16, 2017 /EINPresswire.com/ -- The market for drugs to treat diseases of the brain, spinal cord and nerves in Brazil, India, Russia and China (the BRICs) will all grow at 10% a year or above up to 2020. In the case of China and India this follows on from growth at this high level since 2010. Although the BRICs currently account for only a small proportion of the world's market for these drugs - 10% in 2016 - their large populations and high economic growth rates mean that they present good opportunities for manufacturers of central nervous system drugs.

In contrast with the rapid growth in the BRICs, the neurological drugs market in the USA, easily the world's largest, has been sluggish at 4%, though growing at a slightly faster 6% going forward. The Western European countries and Japan also have only moderate growth in the markets for these central nervous system drugs, so helping to hold back global growth to 5%. The global market will be worth \$83 billion in 2020, around 8% of the total for all pharma.

Drugs for neurological diseases are used to treat disorders such as epilepsy, Alzheimer's Disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders, multiple sclerosis, Parkinson's Disease, neuroinfections, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition.

In the BRICs, greater affordability of treatment resulting from growing GDP per capita and to some degree the advent of low-price generics help account for growth in the markets for these drugs. The top selling neurological medication brands in 2016 include Copaxone, Lyrica, and Tecfidera. The market for these drugs is more concentrated than that for most drugs, as the leading ten competitors account for two-thirds of the total instead of, as in the case of cardiovascular drugs, around one-third. America's Biogen is the market leader, closely followed by the Swiss Hoffman-La Roche, both with close to 12% of global sales; the USA's Johnson and Johnson is in third place with an about 9% share.

One of the trends shaping the market is a partnership with technology companies. Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson's disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions,



and thus reduce the time for trials by 30% to 50%. For instance, in 2016, Michael J. Fox Foundation for Parkinson's Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson's disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer's disease research.

Where to Learn More

Read [Central Nervous System Drugs Market Global Report 2017](#) from [The Business Research Company](#) for information on the following:

Markets Covered: Analgesics, Anti-Parkinson Drugs, Anaesthetics, Anti-Epileptics, Other CNS Drugs
Companies Mentioned: Pfizer Inc., Biogen Idec, Novartis AG, Otsuka, and Teva Pharmaceuticals
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Interested to know more? Here is a full scope of Biologics and Pharmaceutical Drugs Market reports to explore:

1. Biologics Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/biologics-market-global-report-2017/>)
2. Anti-infective Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/anti-infective-drugs-market-global-report-2017/>)
3. Cardiovascular Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/cardiovascular-drugs-market-global-report-2017/>)
4. Pharmaceutical Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/pharmaceutical-drugs-market-global-report-2017/>)
5. Dermatology Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/dermatology-drugs-market-global-report-2017/>)
6. Genito-Urinary Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/genito-urinary-drugs-market-global-report-2017/>)
7. Hematology Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/hematology-drugs-market-global-report-2017/>)
8. Metabolic Disorder Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/metabolic-disorders-drugs-market-global-report-2017/>)
9. Musculoskeletal Disorders Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/musculoskeletal-disorders-drugs-market-global-report-2017/>)
10. Ophthalmology Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/ophthalmology-drugs-market-global-report-2017/>)

11. Gastrointestinal Drugs Market Global Report 2017

(<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/gastrointestinal-drugs-market-global-report-2017/>)

12. Respiratory Drugs Market Global Report 2017

(<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/respiratory-diseases-drugs-market-global-report-2017/>)

13. Oncology Drugs Market Global Report 2017 (<https://www.thebusinessresearchcompany.com/our-research/healthcare/pharmaceuticals/oncology-drugs-market-global-report-2017/>)

About The Business Research Company

Visit TheBusinessResearchCompany.com. The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has research professionals at its office in the UK, India, and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. The Business Research Company's management have more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations. The Business Research Company's Consultant have master's qualifications from top institutes and include MBAs, MSCs, CFAs and CAs. The Business Research Company's Consultants gain training and qualifications from the market Research Society and are trained in advanced research practices, techniques, and ethics.

Oliver Guirdham

The Business Research Company

+44 744 3439350

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.